AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009



    QUEBEC CITY, April 30 /CNW Telbec/ - AEterna Zentaris Inc. (NASDAQ:   AEZS,
TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and
oncology, will announce its first quarter 2009 financial and operating results
before market open on Wednesday, May 6, 2009. The Company will host a
conference call and webcast to discuss these results later that same day at
3:30 p.m., Eastern Time.
    Participants may access the live webcast via the Company's website at
www.aezsinc.com in the "Investors" section, or by telephone using the
following numbers: 416-644-3422, 514-807-8791 or 800-587-1893. A replay of the
webcast will also be available on the Company's website for a period of 30
days.
    The Company further announced that it will hold its Annual Shareholder
Meeting also on Wednesday, May 6, 2009 starting at 10:30 a.m. Eastern Time, in
Rooms 6 and 7 of the Centre Sheraton Montreal Hotel, 1201 René-Lévesque
Boulevard West, in Montreal.

    About AEterna Zentaris Inc.

    AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization. News releases and additional information
are available at www.aezsinc.com.




For further information:

For further information: Investor Relations: Ginette Vallières, Investor
Relations Coordinator, (418) 652-8525 ext. 265, gvallieres@aezsinc.com; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext.
406, pburroughs@aezsinc.com

Organization Profile

Aeterna Zentaris Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890